Compare Amphastar Pharmaceuticals Inc (AMPH) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Estee Lauder Companies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Estee Lauder Companies Inc trades at $83.5 (market cap $29.91B). The key difference: Estee Lauder Companies Inc is far larger — about 36.2× Amphastar Pharmaceuticals Inc's market cap, and Estee Lauder Companies Inc pays a 1.69% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | EL | |
|---|---|---|
Market Cap | $826.08M | $29.91B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $119.61 |
52-Week Low | $16.87 | $67.23 |
Enterprise Value | $1.22B | $36.08B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Estée Lauder (EL) trades at $82.66, up 0.82% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported negative net income of -$1.13B in 2025, though it has beaten EPS estimates in recent quarters. Revenue has declined from $17.7B in 2022 to $14.33B in 2025, while debt-to-asset ratio rose to 36.78%.
The outlook is mixed: analyst consensus is a Buy with a $90.60 price target, but high valuation ratios and profitability challenges pose risks. Positive sentiment from news highlights innovation and industry trends, yet financial performance and macroeconomic pressures remain headwinds for near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
